Latest Articles

  • von Willebrand disease: A guide for the internist
    Varinder Kaur, MD, Omar Elghawy, MD, Saarang Deshpande, MD and David Riley, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 119-127; DOI: https://doi.org/10.3949/ccjm.91a.22033

    The pathophysiology of von Willebrand disease, its subtypes, common presentations of each subtype, diagnostic testing, and management of clinical manifestations of the disease are reviewed.

  • Diagnosis and management of pancreatic cystic lesions for the non-gastroenterologist
    Diagnosis and management of pancreatic cystic lesions for the non-gastroenterologist
    Arjun Chatterjee, MD, Tyler Stevens, MD, FACG, FASGE and Prabhleen Chahal, MD, FACG, FASGE
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 96-102; DOI: https://doi.org/10.3949/ccjm.91a.23019

    A summary of current guidelines from several organizations on the diagnosis and surveillance of pancreatic cystic lesions.

  • Hypertension and severe hyperreninemia in a young man
    Joshua M. Leisring, MD, Jason Lyou, MD, Eshetu Obole, MD and Amy A. Yau, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 103-108; DOI: https://doi.org/10.3949/ccjm.91a.23055

    A 29-year-old man with blood pressure measurements of 152/118 mm Hg and 156/116 mm Hg at 2 separate clinic visits is started on combination antihypertensive therapy and undergoes evaluation for secondary causes of hypertension.

  • In Reply: Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
    Pooja Prasad, MD and Megha Prasad, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 82-83; DOI: https://doi.org/10.3949/ccjm.91c.02002
  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 118;

    In the January 2024 issue, the article “When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?” by Badwan OZ et al [Cleve Clin J Med 2024; 91(1):47–51. doi:10.3949/ccjm.91a.23034] contained an error in Figure 1.

  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Osamah Z. Badwan, MD, Lorenzo Braghieri, MD, Warren Skoza, MD, Ankit Agrawal, MD, Venu Menon, MD and W. H. Wilson Tang, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 47-51; DOI: https://doi.org/10.3949/ccjm.91a.23034

    Evidence from clinical trials supports starting these medications as early as possible in patients hospitalized with acute decompensated heart failure who do not have clear contraindications to them.

  • 2023 Update in ambulatory general internal medicine
    Jason T. Alexander, MD, Simran K. Singh, MD, Sachin D. Shah, MD, Brianna Lambert, MD and Jeremy P. Smith, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 40-46; DOI: https://doi.org/10.3949/ccjm.91a.23056

    Topics reviewed include prevention of chronic kidney disease progression, diet for preventing secondary cardiovascular disease, prevention of kidney-stone recurrence, drug therapy for weight loss, and cholesterol management.

  • Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting
    Shrouq Khazaaleh, MD, Mohammad Alomari, MD, Mamoon Ur Rashid, MD, Daniel Castaneda, MD and Fernando J. Castro, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 33-39; DOI: https://doi.org/10.3949/ccjm.91a.23015

    Malignancy develops in only a small minority of patients with gastric intestinal metaplasia. Recognition of clinical, endoscopic, and histologic features linked with cancer development is critical to identifying patients who require endoscopic surveillance.

  • Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
    Abhayjit Singh, MD and Leslie S. Cho, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 53-63; DOI: https://doi.org/10.3949/ccjm.91a.23058

    Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease.

  • Conjunctival petechiae in infective endocarditis
    Akinori Sekizawa, MD, Ayaka Nagano, MD, Kenichi Hashimoto, MD, PhD and Yosuke Ono, MD, PhD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 20-21; DOI: https://doi.org/10.3949/ccjm.91a.23041

    A 75-year-old-man presented with a 33-day history of intermittent nocturnal fevers of 39°C (102°F) and truncal rashes. The rashes appeared on the same day as the fever.

Pages